USPTO serial 78229836
EPTEST
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HAYES, GINA CLARK
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with EPTEST?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
J. Scott Evans
J SCOTT EVANS ADAMS EVANS PA301 S TRYON STCHARLOTTE NC, 28282U.S. ARMYGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations; antibody preparations; chemical preparations for use in performing polymerase chain reactions (PCR); monoclonal antibodies; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to antigens; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to vaccines; diagnostic preparations and reagents for sale in kit form; biological preparations; biological cultures; cell cultures; cell lines; chemical preparations; cultures of micro organisms; diagnostic preparations; enzymes; genes; DNA; RNA; peptides; polypeptides; proteins; recombinant antibodies; vaccines; including all of the above aforesaid goods for the treatment of amyloidosis, Alzheimer's Disease, Down Syndrome and Mild Cognitive Impairment (MCI); Pharmaceutical preparations; antibody preparations; chemical preparations for use in performing polymerase chain reactions (PCR); monoclonal antibodies; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to antigens; chemical preparations for determination of the reaction of an individual's human leucocyte antigen (HLA) haplotype to vaccines; diagnostic preparations and reagents for sale in kit form; biological preparations; biological cultures; cell cultures; cell lines; chemical preparations; cultures of micro organisms; diagnostic preparations; enzymes; genes; DNA; RNA; peptides; polypeptides; proteins; recombinant antibodies; vaccines; including all of the above aforesaid goods for the treatment of amyloidosis, Alzheimer's Disease, Down Syndrome and Mild Cognitive Impairment (MCI) | ACTIVE | — |
| 010 | Diagnostic test kits; diagnostic test kits for use in polymerase chain reactions (PCR) ; diagnostic test kits and apparatus for determination of an individual's HLA haplotype reaction with vaccines; all the aforesaid for determination of an individual's HLA haplotype reaction with vaccines against Alzheimer's Disease, MCI, amyloidosis and Down Syndrome.; Diagnostic test kits; diagnostic test kits for use in polymerase chain reactions (PCR) ; diagnostic test kits and apparatus for determination of an individual's HLA haplotype reaction with vaccines; all the aforesaid for determination of an individual's HLA haplotype reaction with vaccines against Alzheimer's Disease, MCI, amyloidosis and Down Syndrome. | ACTIVE | — |
| 042 | Scientific, medical and industrial research; vaccine screening; biochemical analysis, biochemical research; diagnosis of predisposition to Alzheimer's Disease, Mild Cognitive Impairment (MCI); amyloidosis and Down Syndrome; disease management; drug design; healthcare; prophylaxis and treatment of medical disorders; prophylaxis, vaccination, vaccine screening, and treatment of Alzheimer's Disease, Down Syndrome, Mild Cognitive Impairment (MCI) and amyloidosis.; Scientific, medical and industrial research; vaccine screening; biochemical analysis, biochemical research; diagnosis of predisposition to Alzheimer's Disease, Mild Cognitive Impairment (MCI); amyloidosis and Down Syndrome; disease management; drug design; healthcare; prophylaxis and treatment of medical disorders; prophylaxis, vaccination, vaccine screening, and treatment of Alzheimer's Disease, Down Syndrome, Mild Cognitive Impairment (MCI) and amyloidosis. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 17, 2004 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 27, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 21, 2003 | CFIT | CASE FILE IN TICRS | — |
| Jun 30, 2003 | PAPER RECEIVED | — |